Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Audio Summaries

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis

Jun 11, 2026

The authors aimed to evaluate the effectiveness of high-dose methotrexate (HD-MTX) as a prophylactic treatment to prevent central nervous system (CNS) relapse in patients with ultra high-risk large B-cell lymphoma (UHR LBCL). An analysis of 1,923 UHR patients revealed no significant difference in the 3-year CNS relapse rates between those treated with HD-MTX and those who were not. These findings suggest that HD-MTX prophylaxis does not provide a meaningful benefit in reducing CNS relapse in this patient population.

The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)

Jun 11, 2026

The authors aimed to evaluate the safety and efficacy of an all-oral regimen combining revumenib, decitabine/cedazuridine, and venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) harboring specific genetic alterations. The study found a composite complete remission (CRc) rate of 71% and a median duration of remission of 10.5 months, indicating that this combination therapy is effective and well-tolerated in heavily pretreated patients.

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer

Jun 4, 2026

This study aimed to evaluate the safety and efficacy of guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor T-cell (CAR T) therapy in patients with metastatic colorectal cancer (CRC) who have limited treatment options. The phase I trial demonstrated an acceptable safety profile, with a 26.3% objective response rate and improved outcomes in patients receiving higher doses of CAR T cells, particularly among those with medium-to-high GUCY2C expression.